Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Strategy of antibiotic therapy in SAP,De-escalate (cefoperazone+metronidazole) or Escalate (meropenem) therapy,which one is better.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Erzhen Chen
• Collaborator: RenJi Hospital
• Treatments: Cefoperazone; Chlorhexidine; Chlorhexidine gluconate; Meropenem; Metronidazole; Somatostatin; Sulperazone; Thienamycins

Criteria

Inclusion Criteria:

• severe Acute Pancreatitis according to Atlanta criteria revisited in 2012

Exclusion Criteria:

• concurrent sepsis or (peri)pancreatic infection caused by a second disease

• patients with chronic organ failure (chronic renal failure needs kidney replacement, chronic heart failure, decompensate hepatic cirrhosis, chronic obstructive pulmonary disease)

• recurrent or endoscopic retrograde cholangiopancreatography (ERCP), or traumatic or operative pancreatitis

• pregnancy, malignancy or immunodeficiency

• a history of allergy to meropenem, cefoperazone and metronidazole

• a history of antibiotic administration within 48 h prior to enrollment

• possible death within 48 h after enrollment